UBS lowered the firm’s price target on Altimmune (ALT) to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial setback, UBS still sees a sizeable opportunity for pemvidutide in nonalcoholic steatohepatitis, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune’s Pemvidutide Advances Towards Phase 3 Trials with Promising Data and Strategic Leadership
- Altimmune Reports Promising Trial Results and Financial Growth
- Altimmune’s Pemvidutide Faces Uncertainty Amid MASH Market Challenges and Pending Developments
- Altimmune reports Q2 EPS (27c), consensus (32c)
- Options Volatility and Implied Earnings Moves Today, August 12, 2025